http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Recursion (RXRX) and MIT researchers unveils Boltz-2 biomolecular model
-
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion to Participate in Upcoming Investor Conferences
-
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
-
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
-
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
-
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
-
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
-
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
-
Recursion Pharmaceuticals (RXRX) Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
-
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
-
Recursion to Participate in Upcoming Investor Conference
-
Recursion Pharmaceuticals (RXRX) Appoints Namandjé Bumpus and Elaine Sun to its Board
-
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
-
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
-
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
-
Recursion's Altitude Lab startup has raised $154 million
-
Altitude Lab Startups Raise $154M in Capital
-
Recursion Pharmaceuticals (RXRX) reports date from phase 2 of REC-994 studies
-
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
-
Recursion Pharmaceuticals (RXRX) Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials
-
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
-
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
-
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
-
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
-
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
-
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
-
Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI) Shareholders Approve the Proposed Merger
-
Recursion and Exscientia Shareholders Approve the Proposed Combination
-
Recursion Pharmaceuticals (RXRX) Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
-
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
-
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
-
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
-
Recursion Pharmaceuticals (RXRX) announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides diffi
-
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
-
Recursion Pharmaceuticals (RXRX) Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphom
-
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
-
Recursion (RXRX) Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for CCM, has Met its Primary Endpoint of Safety and Tolerability
-
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
-
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
-
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
-
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
-
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
-
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
-
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
-
Recursion to Participate in Upcoming Investor Conferences
-
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
-
Recursion Pharmaceuticals (RXRX) Appoints Robert Hershberg as Board Chair
